Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences

BioSpecifics Technologies
Posted on: 31 Aug 18

LYNBROOK, N.Y., Aug. 30, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ : BSTC ), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences in September.

H.C. Wainwright 20th Annual Global Investment Conference at 4:15 p.m. on Thursday, September 6, 2018 in New York, NY.

25th Annual BioCentury NewsMakers in The Biotech Industry Conference at 2:00 p.m. ET on Friday, September 7, 2018 in New York, NY.

A live audio webcast of each presentation can be accessed under the "Events and Presentation" tab in the Investors section of the Company's website at An archived replay of the webcast will be available for 30 days after the live event concludes.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Canada, Europe and Australia. The CCH research and development pipeline includes several additional promising indications, including Phase 3 clinical trials for the treatment of cellulite with top-line data expected in the fourth quarter of 2018. BioSpecifics is managing the development of CCH for the treatment of uterine fibroids the Phase 1 clinical trial is now fully enrolled with top-line data expected in the fourth quarter of 2018. For more information, please visit

Editor's Details

Mike Wood

Last updated on: 31/08/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.